Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
May 10 2022 - 8:00AM
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical
company advancing medicines to solve patients' problems with
current standards of care and provide transformative products to
improve their lives, announced today that the management team will
participate in the H.C. Wainwright Global Investment Conference
from May 23rd to May 26th.
The Aquestive team is scheduled to present on
May 25th at 2:30 pm ET and will host investor meetings at the
conference through May 26th.
A webcast of the presentation will be available
on the "Events and Presentation" page of the Investors section of
the Company's website. A replay of the webcast will be available
for 30 days following the event. For more information, please visit
investors.aquestive.com.
About AquestiveAquestive
Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company
advancing medicines to solve patients’ problems with current
standards of care and provide transformative products to improve
their lives. We are developing orally administered products to
deliver complex molecules, providing novel alternatives to invasive
and inconvenient standard of care therapies. Aquestive has five
commercialized products on the U.S. market, four licensed products
and one stand-alone proprietary product to date, Sympazan®
(clobazam) oral film for the treatment of seizures associated with
Lennox-Gastaut syndrome. Our licensees market their products in
the U.S. and around the world. The Company also
collaborates with pharmaceutical companies to bring new molecules
to market using proprietary, best-in-class technologies, like
PharmFilm®, and has proven drug development and commercialization
capabilities. Aquestive is advancing a late-stage proprietary
product pipeline focused on treating diseases of the central
nervous system, or CNS, and an earlier stage pipeline for the
treatment of severe allergic reactions, including anaphylaxis. For
more information, visit Aquestive.com and follow us on
LinkedIn.
Forward-Looking
StatementCertain statements in this press release include
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,”
“will,” or the negative of those terms, and similar expressions,
are intended to identify forward-looking statements. These
forward-looking statements are subject to the uncertain impact of
the COVID-19 global pandemic on our business including with respect
to our clinical trials including site initiation, patient
enrollment and timing and adequacy of clinical trials; on
regulatory submissions and regulatory reviews and approvals of our
product candidates; pharmaceutical ingredient and other raw
materials supply chain, manufacture, and distribution; sale of and
demand for our products; our liquidity and availability of capital
resources; customer demand for our products and services;
customers’ ability to pay for goods and services; and ongoing
availability of an appropriate labor force and skilled
professionals. Given these uncertainties, the Company is unable to
provide assurance that operations can be maintained as planned
prior to the COVID-19 pandemic.
These forward-looking statements are based on
our current expectations and beliefs and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
Such risks and uncertainties include, but are not limited to, risks
associated with the Company’s development work, including any
delays or changes to the timing, cost and success of our product
development activities and clinical trials for AQST-109 and our
other product candidates; risk of delays in FDA approval of
Libervant® (diazepam) Buccal Film, AQST-109, and our other drug
candidates or failure to receive FDA approval; ability to address
the concerns identified in the FDA’s Complete Response Letter
dated September 25, 2020 regarding the New Drug
Application for Libervant; risk of our ability to demonstrate to
the FDA “clinical superiority” within the meaning of the FDA
regulations of Libervant relative to FDA-approved diazepam rectal
gel and nasal spray products including by establishing a major
contribution to patient care within the meaning of FDA regulations
relative to the approved products as well as risks related to other
potential pathways or positions which are or may in the future be
advanced to the FDA to overcome the seven year orphan drug
exclusivity granted by the FDA for the approved nasal spray product
of a competitor in the U.S., and there can be no assurance
that we will be successful; risk that a competitor obtains FDA
orphan drug exclusivity for a product with the same active moiety
as any of our other drug products for which we are seeking FDA
approval and that such earlier approved competitor orphan drug
blocks such other product candidates in the U.S. for
seven years for the same indication; risk in obtaining market
access for other reasons; risk inherent in commercializing a new
product (including technology risks, financial risks, market risks
and implementation risks and regulatory limitations); risk of
development of our sales and marketing capabilities; risk of
sufficient capital and cash resources, including access to
available debt and equity financing and revenues from operations,
to satisfy all of our short-term and longer term liquidity and cash
requirements and other cash needs, at the times and in the amounts
needed; risks related to the outsourcing of certain marketing and
other operational and staff functions to third parties; risk of the
rate and degree of market acceptance of our product and product
candidates; the success of any competing products, including
generics; risk of the size and growth of our product markets; risks
of compliance with all FDA and other governmental and customer
requirements for our manufacturing facilities; risks associated
with intellectual property rights and infringement claims relating
to the Company’s products; risk of unexpected patent developments;
the impact of existing and future legislation and regulatory
provisions on product exclusivity; legislation or regulatory
actions affecting pharmaceutical product pricing, reimbursement or
access; claims and risks that may arise regarding the safety or
efficacy of the Company's products and product candidates; risk of
loss of significant customers; risks related to legal proceedings
and associated costs, including patent infringement, investigative
and antitrust litigation matters; changes in government laws and
regulations; risk of product recalls and withdrawals; uncertainties
related to general economic, political, business, industry,
regulatory and market conditions and other unusual items; and other
uncertainties affecting the Company described in the “Risk Factors”
section and in other sections included in our Annual Report on Form
10 K, in our Quarterly Reports on Form 10-Q, and in our Current
Reports on Form 8-K filed with the Securities Exchange
Commission. Given those uncertainties, you should not place undue
reliance on these forward-looking statements, which speak only as
of the date made. All subsequent forward-looking statements
attributable to us or any person acting on our behalf are expressly
qualified in their entirety by this cautionary statement. The
Company assumes no obligation to update forward-looking statements
or outlook or guidance after the date of this press release whether
as a result of new information, future events or otherwise, except
as may be required by applicable law.
PharmFilm®, Sympazan® and the Aquestive logo are
registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries:ICR Westwicke Stephanie
Carringtonstephanie.carrington@westwicke.com646-277-1282
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Sep 2023 to Sep 2024